

1 / 36




FIG. 1

2 / 36




FIG. 2

3 / 36





FIG. 3

4 / 36

FIG. 4



5 / 36





FIG. 5

6 / 36



\*p<0.05 VERSUS NO TREATMENT

FIG. 6

7 / 36






FIG. 7

8 / 36

FIG. 8





10 / 36




FIG. 10





FIG. 11

12 / 36



		GATE: G1	GATED EVENTS: 9624			
		TOTAL EVENTS: 10707	QUAD LOCATION: 523,25			
QUAD	EVENTS	% GATED	% TOTAL	X MEAN	Y MEAN	
UL	9499	98.70	88.72	37.11	1120.67	
UR	3	0.03	0.03	5084.96	773.52	
LL	122	1.27	1.14	31.88	11.09	
LR	0	0.00	0.00	***	***	

		GATE: G1	GATED EVENTS: 9526			
		TOTAL EVENTS: 11100	QUAD LOCATION: 523,25			
QUAD	EVENTS	% GATED	% TOTAL	X MEAN	Y MEAN	
UL	4959	52.06	44.68	84.30	1023.41	
UR	1388	14.57	12.50	2377.81	704.20	
LL	2163	22.71	19.49	50.53	6.64	
LR	1016	10.67	9.15	3619.03	4.05	

		GATE: G1	GATED EVENTS: 9561			
		TOTAL EVENTS: 10934	QUAD LOCATION: 523,25			
QUAD	EVENTS	% GATED	% TOTAL	X MEAN	Y MEAN	
UL	7868	82.29	71.96	58.00	1139.33	
UR	310	3.24	2.84	1922.82	897.47	
LL	1171	12.25	10.71	42.10	8.17	
LR	212	2.22	1.94	3153.17	3.62	

		GATE: G1	GATED EVENTS: 9595			
		TOTAL EVENTS: 10970	QUAD LOCATION: 523,25			
QUAD	EVENTS	% GATED	% TOTAL	X MEAN	Y MEAN	
UL	4910	51.17	44.76	84.95	975.19	
UR	1384	14.42	12.62	1937.36	694.49	
LL	1704	17.76	15.53	48.67	7.00	
LR	1597	16.64	14.56	3286.15	2.68	

**FIG. 12**





FIG. 13



15 / 36




FIG. 15

16 / 36




FIG. 16

FIG. 17A




FIG. 17B





FIG. 17C



■ DISEASE FREE

□ UNTREATED CONTROL

■ PS/2 TREATED

■ RAT IgG2b TREATED CONTROL




FIG. 18

19 / 36




FIG. 19

FIG. 20A




FIG. 20B







FIG. 21




22 / 36





\* p VALUES < .05

FIG. 24



25 / 36




FIG. 25

26 / 36

FIG. 26A




FIG. 26B




FIG. 26C




FIG. 27A





FIG. 27B




2022-07-29 00:00

FIG. 28

	DAY 20	DAY27
	PS/2 PLASMA LEVELS	PS/2 PLASMA LEVELS
8-PS/2	NONE DETECTED	NONE DETECTED
9-P2/2	NONE DETECTED	NONE DETECTED
10-PS/2	NONE DETECTED	NONE DETECTED
11-MELPHALAN+PS/2	NONE DETECTED	NONE DETECTED
12-MELPHALAN+PS/2	3.7 µg/ml	NONE DETECTED
13-MELPHALAN+PS/2	NONE DETECTED	NONE DETECTED

29 / 36

FIG. 29



5TGM1 CELLS (1E6) INJECTED (I.V.) ON DAY 0  
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20

GROUPS N=2/GROUP

DISEASE FREE CONTROL  
UNTREATED MYELOMA CONTROL  
PS/2--100 MICROGRAMS/INJECTION  
Sm.Mol. 8809--3mg/kg, 0.3 mg/kg OR 0.03 mg/kg  
Sm.Mol. 9257 CONTROL--3 mg/kg

FIG. 30A




FIG. 30B






FIG. 30C




**FIG. 31A**

31 / 36



**FIG. 31B**



**FIG. 31C**





FIG. 32



5TGM1 CELLS (1E6) INJECTED (I.V.) ON DAY 0  
PS/2 WAS GIVEN ON DAYS 15,16,17,18,19 AND 20  
SMALL MOLECULE WAS GIVEN ON DAYS 15,16 AND 17  
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 21

## GROUPS N=2/GROUP

DISEASE FREE CONTROL  
UNTREATED MYELOMA CONTROL  
PS/2--100 MICROGRAMS/INJECTION  
8809--3mg/kg, 0.3 mg/kg OR 0.03 mg/kg  
9257 CONTROL--3 mg/kg

FIG. 33A

33 / 36




FIG. 33B




FIG. 33C




FIG. 34A




FIG. 34B





FIG. 35



36 / 36

FIG. 36

